X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lapatinib (874) 874
humans (789) 789
index medicus (766) 766
oncology (679) 679
female (658) 658
breast cancer (536) 536
trastuzumab (527) 527
breast neoplasms - drug therapy (502) 502
cancer (319) 319
breast neoplasms - pathology (300) 300
quinazolines - administration & dosage (293) 293
antineoplastic combined chemotherapy protocols - therapeutic use (281) 281
middle aged (280) 280
chemotherapy (274) 274
her2 (269) 269
receptor, erbb-2 - metabolism (255) 255
aged (239) 239
adult (230) 230
metastasis (220) 220
antineoplastic agents - therapeutic use (214) 214
receptor, erbb-2 - antagonists & inhibitors (214) 214
care and treatment (211) 211
breast neoplasms - metabolism (196) 196
treatment outcome (190) 190
skin and connective tissue diseases (188) 188
open-label (169) 169
therapy (169) 169
medicine & public health (165) 165
animals (161) 161
pharmacology & pharmacy (158) 158
antineoplastic agents (156) 156
epidermal growth factor (154) 154
capecitabine (148) 148
tyrosine kinase inhibitor (146) 146
research (145) 145
quinazolines - therapeutic use (141) 141
antimitotic agents (137) 137
survival (136) 136
adjuvant chemotherapy (127) 127
drug therapy (126) 126
pertuzumab (125) 125
receptor, erbb-2 - genetics (125) 125
cell line, tumor (124) 124
breast neoplasms - genetics (121) 121
phase-ii (120) 120
growth-factor receptor (119) 119
hematology, oncology and palliative medicine (118) 118
quinazolines - adverse effects (116) 116
antineoplastic combined chemotherapy protocols - adverse effects (113) 113
analysis (111) 111
antineoplastic agents - administration & dosage (111) 111
antibodies, monoclonal, humanized - administration & dosage (107) 107
expression (107) 107
brain metastases (105) 105
phase-ii trial (105) 105
monoclonal-antibody (103) 103
combination (102) 102
disease-free survival (102) 102
lapatinib plus capecitabine (102) 102
male (101) 101
health aspects (99) 99
clinical trials (97) 97
resistance (97) 97
mice (93) 93
neoplasm metastasis (93) 93
cancer therapies (92) 92
breast-cancer (91) 91
tumors (90) 90
antineoplastic agents - pharmacology (89) 89
multicenter (87) 87
metastatic breast cancer (86) 86
receptor (86) 86
article (85) 85
quinazolines - pharmacology (85) 85
prognosis (84) 84
protein kinase inhibitors - administration & dosage (84) 84
antibodies, monoclonal, humanized (83) 83
antineoplastic agents - adverse effects (83) 83
breast neoplasms - mortality (82) 82
efficacy (82) 82
neoplasms (82) 82
protein kinase inhibitors - therapeutic use (81) 81
trastuzumab - administration & dosage (81) 81
deoxycytidine - analogs & derivatives (79) 79
drug resistance, neoplasm (79) 79
growth (78) 78
egfr (77) 77
paclitaxel (77) 77
aged, 80 and over (75) 75
brain neoplasms - secondary (75) 75
cancer research (75) 75
safety (75) 75
1st-line treatment (74) 74
erbb-2 protein (74) 74
fluorouracil - administration & dosage (74) 74
tyrosine (74) 74
deoxycytidine - administration & dosage (73) 73
kinases (73) 73
molecular targeted therapy (73) 73
neoadjuvant therapy (73) 73
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1025) 1025
French (11) 11
Japanese (9) 9
German (3) 3
Chinese (1) 1
Polish (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 07/2014, Volume 32, Issue 19, pp. 2078 - 2099
Journal Article
The Oncologist, ISSN 1083-7159, 04/2009, Volume 14, Issue 4, pp. 320 - 368
Learning Objectives Contrast the current strengths and limitations of the three main slide‐based techniques (IHC, FISH, and CISH) currently in clinical use for... 
Prognosis | CISH | IHC | FISH | Lapatinib | Review | HER‐2 | Trastuzumab | HER-2 | SURGICAL ADJUVANT BREAST | C-ERBB-2 ONCOPROTEIN EXPRESSION | TOPOISOMERASE-II-ALPHA | LONG-TERM SURVIVAL | IN-SITU HYBRIDIZATION | PATHOLOGICAL COMPLETE RESPONSE | CIRCULATING TUMOR-CELLS | ONCOLOGY | EPIDERMAL-GROWTH-FACTOR | C-ERB B-2 | NEOADJUVANT ENDOCRINE THERAPY | Immunohistochemistry | Humans | RNA, Messenger - analysis | Bevacizumab | Antibodies, Monoclonal, Humanized | Breast Neoplasms - chemistry | Anthracyclines - administration & dosage | In Situ Hybridization | Polymerase Chain Reaction | Female | Quinazolines - administration & dosage | Gene Expression Regulation, Neoplastic - drug effects | Receptor, ErbB-2 - drug effects | Everolimus | Sirolimus - analogs & derivatives | Biomarkers, Tumor - analysis | Pyrimidines - administration & dosage | Treatment Outcome | Evidence-Based Medicine | Breast Neoplasms - drug therapy | Up-Regulation - drug effects | Sirolimus - administration & dosage | Taxoids - administration & dosage | Pyrazoles - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Survival Analysis | Breast Neoplasms - mortality | Receptor, ErbB-2 - analysis | Neoplasm Staging | Practice Guidelines as Topic | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1317 - 1325
Summary Background Neoadjuvant chemotherapy with trastuzumab for patients with HER2 -positive breast cancer can produce a pathological complete response in the... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | LAPATINIB | WOMEN | MULTICENTER | PREOPERATIVE CHEMOTHERAPY | THERAPY | ONCOLOGY | DISEASE | OPEN-LABEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymph Nodes - pathology | Lymph Nodes - surgery | United States | Humans | Middle Aged | Mastectomy - methods | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Neoplasm Grading | Fluorouracil - adverse effects | Time Factors | Adult | Female | Chemotherapy, Adjuvant | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Biomarkers, Tumor - analysis | Kaplan-Meier Estimate | Paclitaxel - adverse effects | Stroke Volume - drug effects | Treatment Outcome | Lymphatic Metastasis | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Aged | Receptor, ErbB-2 - analysis | Neoplasm Staging | Trastuzumab | Epirubicin - adverse effects | Medical colleges | Care and treatment | Anthracyclines | Cyclophosphamide | Adjuvant treatment | Clinical trials | Breast cancer | Product development | Fluorouracil | Cancer | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 3, pp. 497 - 504
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 32, pp. 3626 - 3634
Purpose Neratinib is a potent irreversible pan-tyrosine kinase inhibitor with antitumor activity and acceptable tolerability in patients with human epidermal... 
ADJUVANT CHEMOTHERAPY | HKI-272 | TRIAL | THERAPY | SOLID TUMORS | TRASTUZUMAB | ONCOLOGY | TYROSINE KINASE INHIBITOR | PHASE-II | EXPANDED ACCESS | LAPATINIB PLUS CAPECITABINE | Capecitabine | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Diarrhea - chemically induced | Quinolines - administration & dosage | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Paresthesia - chemically induced | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Administration, Oral | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Breast Neoplasms, Male - drug therapy | Breast Neoplasms - drug therapy | Syndrome | Breast Neoplasms, Male - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Breast Neoplasms, Male - pathology | Deoxycytidine - analogs & derivatives | Quinolines - adverse effects | Trastuzumab | Index Medicus
Journal Article
by Martin, Miguel and Holmes, Frankie A and Ejlertsen, Bent and Delaloge, Suzette and Moy, Beverly and Iwata, Hiroji and von Minckwitz, Gunter and Chia, Stephen K L and Mansi, Janine and Barrios, Carlos H and Gnant, Michael and Tomašević, Zorica and Denduluri, Neelima and Šeparović, Robert and Gokmen, Erhan and Bashford, Anna and Ruiz Borrego, Manuel and Kim, Sung-Bae and Kim, Seung Jin and Jakobsen, Erik Hugger and Ciceniene, Audrone and Inoue, Kenichi and Overkamp, Friedrich and Heijns, Joan B and Armstrong, Anne C and Link, John S and Joy, Anil Abraham and Bryce, Richard and Wong, Alvin and Moran, Susan and Yao, Bin and Xu, Feng and Xu, Binghe and Auerbach, Alan and Buyse, Marc and Chan, Arlene and Harvey, Vernon and Tomek, Rudolf and Robert, Nicholas J and Gore, Ira and Smith, John W and Smith, Julie C and Masuda, Norikazu and Di Sean Kendall, S and Harker, William Graydon and Petrakova, Katarina and Guerrero Zotano, Angel and Simon, Amparo Ruiz and Konstantinovic, Zora Neskovic and Iannotti, Nicholas O and Tassone, Pierfrancesco and Rodriguez, Gladys I and Jáñez Martinez, Noelia and Crespo Massieu, Carmen and Smickoska, Snezana and Somali, Isil and Yilmaz, Ugur and Alonso, Mirta Garcia and Rosales, Adolfo Murias and Cold, Soeren and Knoop, Ann Soegaard and Patt, Debra and Hellerstedt, Beth A and Morales Murillo, Serafin and Mayer, Ingrid A and Means-Powell, Julie Ann and Hui, Rina and Senecal, Francis M and De Boer, Richard Hendry and Shen, Zhenzhou and Luczak, Adam Andrzej and Chui, Joanna W.Y and Chui, Stephen and Tsang, Janice Wing-hang and Lang, Istvan and Rai, Yoshiaki and Hozumi, Yasuo and Ten Tije, Albert J and Bhandari, Manish and Osborne, Cynthia R.C and Ohtani, Shoichiro and Higaki, Kenji and Watanabe, Junichiro and Watanabe, Kenichi and Taguchi, Tetsuya and Taguchi, Kazunori and Takahashi, Masato and Filipovic, Sladjana and Hansen, Vincent L and Rao, Vijayarama Phooshkooru and Gupta, Manish and Petrov, Petar and Coudert, Bruno and Vojnovic, Zeljko and Polya, Zsofia and Miyaki, Toshiko and Yamamoto, Naohito and Brincat, Stephen and Lesniewski-Kmak, Krzysztof and Chmielowska, Ewa and ... and ExteNET Study Grp and ExteNET Study Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1688 - 1700
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2018, Volume 29, Issue 3, pp. 646 - 653
Journal Article
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2017, Volume 7, Issue 1, pp. 3964 - 15
Journal Article